Hepatitis B Virus Surface Antigen Seroclearance and Seroreversion:A Cohort Study on HBeAg positive C

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户:liongliong512
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Background:Hepatitis B surface antigen clearance induced by interferon-α is associated with favorable clinical outcome.In this study,we investigated HBsAg kinetics during pegIFNα treatment and durability of HBsAg seroclearance,aiming to promote HBsAg seroclearance by response-guided therapy(RGT).
其他文献
Background:Non-alcoholic fatty liver disease(NAFLD),ranging from nonalcoholic fatty Liver(NAFL) to progressive non-alcoholic steatohepatitis(NASH) and fibrosis,has become an increasingly common health
会议
Background:Host genetic factor is one of important reasons for different response of antiviral treatment in chronic hepatitis B.IL-12 play an important role in immune to HBV.IL12A rs568408 is associat
会议
Background:Therapeutic strategy to activate host innate immunity,like toll-like receptor 7(TLR7) agonist,had a great potential for the treatment of chronic hepatitis B(CHB).Here we investigated the mo
会议
Background:Objectives:Fuzheng Huayu(FZHY) capsule,a Chinese medicine,is widely administrated to treat hepatic fibrosis and cirrhosis in the clinic in China for twenty years.This abstract is about to s
会议
Background:The zinc finger protein A20(also known as TNFAIP3) is a cytoplasmic protein and mediates the regulation of ubiquitin-dependent signaling in inflammation and immunity.Complex immune networks
会议
Background:Incidence of NAFLD(nonalcoholic fatty liver disease) is increasing as a cause of chronic liver disease.Also,obesity and diabetes are risk factors for the development of hepatocellular carci
会议
Background:It is of great importance to early and accurately predict the prognosis of patients with acute-onchronic hepatitis B liver failure(ACHBLF) for optimum management.The promoter methylation of
会议
Background:Hepatitis B virus core-related antigens(HBcrAg) are comprised of hepatitis B core antigen(HBcAg),hepatitis E antigen(HBeAg) and a 22 kDa precore protein(P22cr).HBcrAg concentrations were we
会议
Background:To compare the efficacy and safety of 52-week sequential therapy with telbivudine and other nucleoside analogs(NAs) in HBeAg-positive Chronic Hepatitis B Patients(CHB) patients with subopti
会议
Background:To characterize roles of serum hepatitis B virus markers(HBVM) quantitations in the prediction of natural phases of HBV infection.Methods:149 patients of chronic hepatitis B(CHB) undergone
会议